November 19, 2026
Tonight: why women are still paying for birth control that’s supposed to be free, the birth helpers nobody is checking on, and more.
— Meghan McCarthy
STILL PAYING FOR WHAT’S SUPPOSED TO BE FREE
About one in five privately insured women using prescription birth control paid some or all of the cost out of pocket, according to a KFF survey of around 3,500 women ages 18 to 49. Most private plans are required to cover birth control without cost-sharing, but only 40% of women surveyed knew that. Among uninsured birth control users, 18% stopped using a method in the past year because they couldn’t afford it. Reported use of fertility-awareness methods rose from 13% to 18% since 2024, while use of a partner’s vasectomy rose from 10% to 14%. Opill, the first over-the-counter daily birth control pill, has been available since March 2024, but just 2% of women surveyed have used it.
THE FDA PICK WHO DIDN’T MAKE IT
The White House withdrew Heidi Overton’s nomination to lead the FDA a day before a scheduled Senate committee vote. Overton, a physician and abortion opponent, wrote in a 2023 policy brief that Congress should strictly regulate mifepristone and criticized policies allowing abortion pills to be mailed. Her nomination drew opposition from Democrats and skepticism from Republicans over vaccines, abortion policy, and her independence from Trump. Senate HELP committee chair Bill Cassidy had called her support for breaking up combination vaccines like MMR “almost disqualifying,” though he later said she could have won confirmation. The FDA is conducting a safety review of mifepristone expected to conclude in March. Republicans are running out of time to confirm Trump’s remaining nominees before Democrats take control of the Senate in January.
THE QUESTIONNAIRE THAT CAUGHT IT
Olivia Munn’s genetic test and mammogram came back negative. But a breast cancer risk questionnaire flagged her as high risk, prompting her doctor to order an MRI. She was diagnosed with stage 1 cancer in both breasts in 2023. Now she’s backing the Know Your Risk Act, a bipartisan bill introduced Wednesday by Sens. Mark Kelly and Shelley Moore Capito, with a House companion. It would create an interagency task force to promote wider, more consistent use of validated breast cancer risk-assessment tools. Susan G. Komen, which backs the bill, says providers currently use different tools with no standard approach. Breast cancer is the leading cause of cancer death among women ages 20 to 49, according to Komen.
A YARDSTICK FOR PERIMENOPAUSE
A new 16-question scale for measuring perimenopause symptoms performed well in a study of 1,255 U.S. women ages 35 to 59, including 633 who identified as perimenopausal, researchers reported in the journal Menopause. Women gave consistent answers when they retook it a week or two later, and scores tracked closely with an established menopause questionnaire. The scale covers hot flashes, mood, sex, and physical changes like digestive and hair problems that older checklists, often designed for postmenopausal women, may miss. Women ages 45 to 54 reported the heaviest symptom burden overall. Flo Health developed the scale with Mayo Clinic clinicians and already uses it for its in-app “Peri Score.” Participants were recruited online and reported their own menopause stage.
WHO’S WATCHING THE DOULAS?
Medicaid now covers doula services in 28 states, up from eight in 2022, and new doula provider registrations have grown 11-fold since 2019. But there are no national standards for doula training or qualifications, and no single body oversees complaints across the profession, The Atlantic reports. Mothers described doulas who skipped appointments, showed up hours late, or urged them to decline Pitocin against medical advice. One woman paid $2,500 for a doula who arrived for only the last 10 or so minutes of labor. Doula support has been linked to fewer C-sections and better birth experiences, helping drive demand for a profession with uneven oversight.